Cart
sales@molnova.com
UCL-TRO-1938
CAS No. 2919575-27-0
UCL-TRO-1938( —— )
Catalog No. M37137 CAS No. 2919575-27-0
UCL-TRO-1938 is a subtype-selective PI3Kα allosteric activator with cardioprotective and neuroregenerative effects.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 117 | In Stock |
|
| 5MG | 117 | In Stock |
|
| 10MG | 187 | In Stock |
|
| 25MG | 392 | In Stock |
|
| 50MG | 616 | In Stock |
|
| 100MG | 986 | In Stock |
|
| 200MG | 1321 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameUCL-TRO-1938
-
NoteResearch use only, not for human use.
-
Brief DescriptionUCL-TRO-1938 is a subtype-selective PI3Kα allosteric activator with cardioprotective and neuroregenerative effects.
-
DescriptionUCL-TRO-1938 is a potent allosteric activator of PI3Kα with an EC50 value of approximately 60 μM. UCL-TRO-1938 can induce cell proliferation and has cardioprotective and neural regeneration effects.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPI3K
-
RecptorPI3K
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2919575-27-0
-
Formula Weight456.58
-
Molecular FormulaC27H32N6O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (109.51 mM; Ultrasonic (<80°C)
-
SMILESO=C(N1C=2C(=CC=CC2CC1)NC=3C=CN=C(C3)NC4=CC=C(C=C4)N5CCN(CC)CC5)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Grace Q Gong, et al. A small-molecule PI3Kα activator for cardioprotection and neuroregeneration. Nature. 2023 Jun;618(7963):159-168.?
molnova catalog
related products
-
IPI-549
IPI-549 (IPI549) is a?potent, highly selective, orally active inhibitor of PI3Kγ with IC50 of 16 nM.
-
Parsaclisib HCl
Parsaclisib HCl is a selectve PI3Kδ inhibitor with antitumor activity. Parsaclisib demonstrates potent activity with IC50 values ranging from 0.2 to 2 nM.
-
Loureirin A
Loureirin A has an inhibitory effect on platelet activation perhaps through an impairment of PI3K/Akt signaling.Loureirin A negatively affects agonist-induced platelet aggregation such as collagen collagen-related peptide (CRP) ADP and thrombin.
